New agents and new formulations for the treatment of ovarian cancer Journal Article


Author: Sabbatini, P.
Article Title: New agents and new formulations for the treatment of ovarian cancer
Keywords: vasculotropin; cancer survival; vascular endothelial growth factor a; survival rate; unclassified drug; thalidomide; clinical trial; cancer localization; cancer recurrence; bevacizumab; cisplatin; erlotinib; cancer combination chemotherapy; drug efficacy; drug potentiation; drug safety; note; paclitaxel; drug megadose; antineoplastic agent; colorectal cancer; ovarian neoplasms; carboplatin; ovary cancer; antineoplastic combined chemotherapy protocols; recurrence; cyclophosphamide; vasculotropin inhibitor; angiogenesis; cetuximab; survival time; antibodies, monoclonal; gefitinib; vatalanib; predictive value of tests; remission induction; tamoxifen; cancer relapse; intestine perforation; ca 125 antigen; ca-125 antigen; trabectedin; quinazolines; metabolic disorder; drug delivery system; electrolyte disturbance; drug formulation; dioxoles; isoquinolines; oregovomab; tetrahydroisoquinolines; 1 acylglycerophosphocholine acyltransferase; endothelial cell growth factor; hyb 2055; imoxine
Journal Title: Clinical Advances in Hematology & Oncology
Volume: 3
Issue: 11
ISSN: 1543-0790
Publisher: Millennium Medical Publishing, Inc  
Date Published: 2005-11-01
Start Page: 840
End Page: 842
Language: English
PUBMED: 16491624
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 24 October 2012" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Paul J Sabbatini
    258 Sabbatini